New York Launches Study on CBD and THC for Patients With Inflammatory Bowel Disease

The New York State Office of Cannabis Management today announced the launch of a new observational research study “aimed at better understanding patients living with moderate Inflammatory Bowel Disease (IBD).” This study “will examine how oral doses of CBD and THC may impact quality of life in adults with clinically confirmed IBD.”

IBD is a group of chronic, lifelong disorders that cause long-term inflammation in the digestive tract. The Office is studying how medical cannabis may affect the day-to-day experiences of patients living with persistent IBD symptoms. This comprehensive research study reflects New York’s growing leadership in cannabis science and aims to strengthen understanding of how cannabinoids may support patients managing complex chronic health conditions.

“New York continues to contribute to a more informed and science driven approach to cannabis policy and public health,” said John Kagia, Acting Executive Director of the Office of Cannabis Management. “This exciting study reflects OCM’s commitment to ensuring that policymakers, healthcare providers, and patients have access to robust data that drives informed decision making and continued innovation across the cannabis industry.”

“Patients living with gastrointestinal conditions often face daily challenges that can significantly impact their quality of life,” said Dr. Junella Chin, Chief Medical Officer of the New York State office of Cannabis Management. “Advancing comprehensive cannabis research is essential to expanding treatment options, underpinning support for patient care and strengthening our understanding of how cannabis could support health and wellness,”-

 “Patients with inflammatory bowel disease live with chronic symptoms, including stomach pain and nausea, which can impact a person’s overall quality of life,” said State Health Commissioner Dr. James McDonald. “The launch of this study reflects New York State’s commitment to advancing cannabis science and research to better understand the long-term therapeutic benefits of medical cannabis beyond anecdotal reports.”

While many patients report benefits from medical cannabis, researchers and healthcare professionals continue to emphasize the need for more high-quality data to better understand efficacy and long-term impacts. Additionally, OCM commends Vireo and Green Thumb Industries for their vital role as dispensing partners for the study. Their collaboration helps ensure enrolled patients have access to safer and regulated medical cannabis products.

“Research like this helps move the conversation about cannabis from anecdotal experiences to measurable data-driven patient outcomes,” said Dr. Nakesha Abel, Director of Scientific Programs & Research and Principal Investigator for the study. “By investing in and conducting research, OCM is contributing to a deeper understanding of the full impact and therapeutic potential of cannabis.”

Findings from this study, titled A Pilot Prospective Observational Study to Assess the Effects of Cannabidiol (CBD) and Delta-9-Tetrahydrocannabinol (THC) on Inflammatory Bowel Disease Symptoms, may help inform future medical research, support healthcare providers and patients, and contribute to the development of evidence-based cannabis policy.

For more information visit cannabis.ny.gov/ibd-study-2026.